Introduction
Bone morphogenetic proteins (BMPs) are potent mediators of osteogenesis both during bone formation and fracture healing and are the most commonly used growth factors to stimulate bone tissue formation experimentally. Indeed, both BMP-2 and BMP-7 are approved for use clinically [1] [2] [3] [4] [5] . However, due to the fast release of extremely high doses of recombinant protein (4.2-8.4 mg) required to enhance bone repair, there have been many reports of adverse side effects including ectopic bone formation, cytotoxicity, increased incidence of cancer as well as some reports of inadequate healing [6, 7] . Methods to control the release of these proteins and decrease the dose to more https://doi.org/10.1016/j.jconrel.2018.05.022 Received 15 January 2018; Received in revised form 24 April 2018; Accepted 18 May 2018 physiological levels might allow for bone repair while reducing or even eliminating the risk of side-effects. Non-viral gene therapy can be used to transfect cells with genes encoding for therapeutic proteins, such as BMPs, inducing the transfected cells to produce physiological quantities of specific protein in a controllable manner [8, 9] . Furthermore, nonviral gene delivery can ensure sustained but ultimately transient expression of the therapeutic which is an important safety aspect associated with gene therapy.
Within our laboratory, we have developed a series of gene-activated scaffold platforms capable of efficiently delivering nucleic acids to cells [10] [11] [12] [13] [14] [15] . In particular, a gene-activated scaffold comprised of chitosan nanoparticles carrying plasmid DNA (pDNA) incorporated into a collagen hydroxyapatite scaffold resulted in high transfection efficiency with negligible toxicity [16] and successful transfection of host cells when implanted in vivo [17] making it highly translatable as it can be manufactured to be an off-the-shelf product. When used to deliver pDNA encoding both BMP-2 and vascular endothelial growth factor (VEGF), the gene-activated scaffold significantly accelerated bone formation over untreated and gene-free scaffold controls [17] . Interestingly, we found that the delivery of plasmid BMP-2 (pBMP-2) alone was not sufficient to enhance bone formation, thus we sought to improve the efficiency of the pBMP-2-activated scaffold by investigating the potential of modified BMP-2 encoding plasmids (Fig. 1A) .
When first expressed, BMPs are large inactive molecules which must be proteolytically cleaved in order to activate their specific receptors. Active BMPs exist as dimers, molecular structures with two sub-units. They can exist as homodimers, where both sub-units are identical, such as BMP-2, and also as heterodimers, where the sub-units are different, for example BMP-2/4 and BMP-2/7. While both types are active, some studies have demonstrated that heterodimers such as BMP-2/4 and BMP-2/7 are more active than homodimers [18] [19] [20] . For this reason, we sought to investigate the use of a multi-cistronic plasmid encoding BMP-2 and BMP-7 (Fig. 1B) which may induce expression of BMP-2/7 heterodimers and enhance the efficiency of the gene-activated scaffold [20] .
To ensure maximum efficiency of a plasmid, strategies that allow for fast transcription and more efficient translation of gene to protein can be employed [21] . Genes are made up of protein-coding regions called exons, and non-coding regions called introns which are subsequently removed by spliceosomes before mature messenger RNA (mRNA) leaves the nucleus [22, 23] . During gene transcription, introns as well as exons are copied, increasing the time and energy required to form mRNA [24] . Furthermore, during translation of mRNA to protein, codons are translated into amino acids which subsequently form proteins. Synonymous codons can have the same amino acid coding potential, however, there is evidence of preferential use within a group of synonymous codons [25] . Genes that are regularly and highly expressed are typically made up of codons that can be decoded by abundant transfer RNAs (tRNAs) while rarely expressed genes show no preference or contain codons that require rare tRNAs [26] . Therefore, by choosing codons that are used often in place of rarely used codons, referred to as codon optimisation, protein expression can be significantly enhanced [27] . In a previous study, to streamline transcription while also increasing protein production, an artificial highly truncated intron of 96 bases was inserted into the BMP-2 gene and codon optimisation was performed. This has led to faster transcription of the encoded gene and enhanced protein production and this novel plasmid is referred to as pBMP-2-Advanced [28] (Fig. 1C) . Fig. 1 . Plasmid maps of different BMP-2 encoding plasmids tested in this study.
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Journal of Controlled Release 283 (2018) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Finally, the promoter sequence in a plasmid also has an effect on transcription efficiency, with the cytomegalovirus (CMV) promoter being the most commonly used due to its ability to drive high levels of mRNA transcription [29] . However, the elongation factor 1α (EF1α) promoter has also been shown to be an efficient alternative particularly in mesenchymal stem cells (MSCs) [30] . To test which promoter sequence was more efficient in promoting transcription of the BMP-2 gene, two different versions of the pBMP-2-Advanced plasmid were tested, containing either the CMV or the EF1α promoter [28] (Fig. 1D) .
The objective of this study was to investigate if using a series of modified BMP-2 plasmids could enhance the efficacy of a pBMP-2 geneactivated scaffold. Using previously optimised chitosan (CS) nanoparticles for gene delivery [16] , we initially compared the modified plasmids; p CMV BMP-2/7, p CMV BMP-2-Adv, and p EF1α BMP-2-Adv to a previously used p CAG BMP-2 construct and assessed BMP-2 protein production by transfected MSCs, and BMP-2 protein functionality by quantifying MSC osteogenesis. The CS nanoparticles carrying each plasmid were then incorporated into collagen-hydroxyapatite bonemimicking scaffolds [31] , thus forming gene-activated scaffolds, and the effect of each plasmid on MSC osteogenesis was assessed. Finally, cell-free gene-activated scaffolds were implanted into critical sized calvarial defects using an established rat model and bone healing at the early time-point of four weeks was analysed to assess the ability of the gene-activated scaffolds to accelerate bone formation.
Materials and methods

2.1.
Comparison of BMP-2 protein production and functionality following transfection with modified BMP-2 plasmids 2.1.1. Plasmid propagation Plasmid DNA (pDNA) encoding human bone morphogenetic protein-2, under the control of a chimeric CMV-beta actin promoter (CAG), was kindly donated by Prof. Kazihusa Bessho, Kyoto University, Japan [9] and compared to a series of BMP-2 constructs developed in the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, namely, pBMP-2/7 [20] , pBMP-2-Advanced (both under the control of the CMV promoter) and pBMP-2-Advanced under the control of the EF1α promoter [28] . Green fluorescent protein pDNA was used as a 'non-osteogenic' control plasmid and was purchased from Lonza. All pDNA was propagated in Top10 competent E.coli cells (Invitrogen) and purified and collected following amplification using an Endotoxin free Maxi-prep kit (Qiagen, UK).
Chitosan-pDNA nanoparticle formulation
Oligomeric chitosan (Mw 7.3 kDa; DD > 97%) was supplied by Novamatrix, FMC Biopolymer, Norway. Nanoparticles were formulated by electrostatic interaction between cationic chitosan and anionic pDNA. Nanoparticles were allowed to equilibrate for 30 min at room temperature before use. The ratio of chitosan to pDNA (N/P ratio) was kept constant at 20. The pDNA dose was varied from 0.5 μg to 10 μg in Fig. 2 and the optimal dose of 2 μg was chosen for all further experiments [16] . For each experiment, seven groups were assessed as outlined in Table 1 below.
Mesenchymal stem cell culture
MSCs, isolated from rat bone marrow, were expanded in Dulbecco's Modified Eagles Medium supplemented with 2% penicillin/streptomycin, 10% FBS (Labtech, UK), 1% glutamax (Biosciences, Ireland) and 1% non-essential amino acids (Biosciences, Ireland). Cells were passaged at 70-90% confluency and expanded to passage 5 for all experiments.
Mesenchymal stem cell transfection in 2D culture
MSCs were seeded at a density of 5 × 10 4 cells per well in 6 well adherent plates (Corning, Costar, Ireland) 24 h prior to transfection.
Media was removed from cells 1 h prior to transfection and cells were washed in PBS (Sigma-Aldrich, Ireland) and 1 mL of OptiMEM (Gibco, Ireland) was added. Nanoparticles were made as described in Section 2.1.2 and, following complexation, OptiMEM was added in a 1:1 ratio to the nanoparticle mixture to produce the transfection medium of which 500 μL was added to each well. After 4 h, transfection media was removed, cells were washed twice in PBS and growth media was replenished.
2.1.5. Enzyme-linked immunosorbent assay (ELISA) ELISAs (R&D Systems, Biotechne, UK) were used to quantify the levels of BMP-2 expressed by cells transfected with each variant of BMP-2 plasmid as well as for all control groups. The cell culture supernatant was collected and analysed at days 1, 3, 7 and 14. Assays were carried out according to the manufacturer's instructions and the absorbance of each sample was read at 450 nm using a Varioskan Flash multimode plate reader (Fisher Scientific, Ireland). The quantity of BMP-2 protein present was deduced by calculating against a standard curve.
Assessment of cytotoxicity using MTT assay
MSCs were transfected as described in Section 2.1.4 and an MTT cell proliferation assay kit (Abcam) was carried out at 3 days post-transfection. This is a metabolic assay where active cellular enzymes reduce the MTT dye to formazan crystals. Briefly, 50 μL of MTT Reagent was added to the cells in 50 μL of serum-free media and incubated for 3 h at 37°C. After 3 h 150 μL of MTT Solvent was added to dissolve the formazan crystals, formed by metabolically active cells, leaving behind a purple colour. The intensity of the resulting colour was read at an absorbance of 570 nm using a reference wavelength of 630 nm using a Varioskan Flash multimode plate reader (Fisher Scientific, Ireland).
Preparation of cells for fluorescent imaging
pDNA was tagged with a Cy3 fluorophore using a Label IT® Nucleic acid labelling kit (Mirus Bio LLC) as per manufacturer's instructions. MSCs were transfected as described in Section 2.1.4. Five hours posttransfection, the media was removed and the cells were washed with PBS. The cells were fixed by adding 4% paraformaldehyde for 15 min before washing in PBS. To permeabilise the cells, 0.1% Triton X-100 solution was added before addition of a HCA cell mask green stain (Invitrogen®) was added to stain the cell membrane and left for 30 min before being removed and washed. Finally, Hoescht 33,258 blue stain was added to stain the nucleus for 5 min prior to final washing in PBS. Images were acquired using an automated Olympus Scan^R screening microscope with a 20×/0.60 NA LUCPLFLN objective.
MSC osteogenesis assay
To assess if the BMP-2 protein produced by transfected cells was functional, an MSC osteogenesis assay was carried out following transfection as described in Section 2.1.3. After 5 h, OptiMEM was removed and replaced with growth media (Section 2.1.3) for three days before being changed to osteoinductive media which contained DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 mM β-glycerophosphate, 50 μM ascorbic acid 2-phosphate and 100 nM dexamethasone. Media was replaced three times per week until day 14 post-transfection. Cells were harvested at days 1, 3, 7 and 14 and ALP activity and DNA content was quantified. Briefly, cells were lysed using 0.2 M sodium carbonate buffer containing 1% Triton X-100. DNA content was measured using a Quant-iT™ PicoGreen® dsDNA assay (Invitrogen, UK) according to manufacturer's protocol and DNA concentration was deduced using a standard curve. The same cell lysate was used to assess ALP activity using a SensoLyte® pNPP Alkaline Phosphatase assay kit (Cambridge Biosciences, Ireland). ALP substrate was applied to the samples and the absorbance measured at 405 nm. ALP concentration was deduced using a standard curve. Calcium content was quantified at day 14 using a Stanbio calcium assay (Calcium CPC Liquicolour, Stanbio Inc., USA). Briefly, media was removed and cells were rinsed with 1 mL of PBS. One mL of 0.5 M HCl was then added to each well and the contents of each well were scraped into microcentrifuge tubes and left to shake overnight at 4°C. Calcium levels were then quantified according to the manufacturer's instructions against a standard curve.
2.2.
Comparison of BMP-2 protein functionality following transfection with modified BMP-2 plasmids on a 3D collagen hydroxyapatite scaffold 2.2.1. Scaffold fabrication A collagen hydroxyapatite scaffold was prepared as per patented protocol [32] ; Briefly, 1.8 g of collagen (Southern Lights Biomaterials, New Zealand) was blended in 0.5 M HOAc 15,000 rpm for 90 min. Hydroxyapatite (200 wt%) was dissolved separately in 0.5 M HOAc and added slowly to the collagen slurry (10 mL/h) while maintaining dispersion at 15,000 rpm. Gas was removed from the slurries using a vacuum pump prior to freeze-drying (Advantage EL, Vis-Tir Co., Gardiner NY) to a final freezing temperature of −40°C. The scaffolds were cross linked dehydrothermally (DHT) at 105°C for 24 h at 0.05 bar in a vacuum oven (Vacucell 22; MMM, Germany), followed by chemical crosslinking using a mixture of 6 mM N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 5.5 mM N-Hydroxysuccinimide (NHS). Cylindrical scaffolds (10 mm diameter) were used in transfection experiments. For in vivo experiments, scaffolds were manufactured Fig. 2 . A pDNA dose response study to determine the optimal pDNA dose for transfection. Fluorescent microcopy images show increasing evidence of nanoparticle aggregation with increasing pDNA dose with A) 0.5 μg; B) 1 μg; C) 2 μg; D) 5 μg; and E) 10 μg. The 2 μg pDNA dose inducing the highest protein production by cells 3 days post-transfection as determined by ELISA (F) and high concentrations of pDNA (10 μg/well) induced significant cellular toxicity. Data plotted represents mean ± SD where n = 3. Two-way ANOVA followed by Bonferoni post hoc analysis was performed and *** indicates p < 0.001 compared to other doses in F and compared to untreated controls (represented by the dashed line) in G. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] with a diameter of 8 mm and a height of 1.5 mm to fit the defect and reflect the thickness of native calvarial bone.
Gene-activated scaffold fabrication
Scaffolds were manufactured as described in Section 2.2.1 and nanoparticles were made as described in Section 2.1.2 as optimised previously [16] . CS-pDNA nanoparticles were formulated at an N/P ratio of 20 containing a 2 μg load of each BMP-2 plasmid. Scaffolds were hydrated in PBS before use and nanoparticles were incorporated by soak-loading onto the scaffold before MSC seeding. After 24 h the scaffolds were moved to fresh 24 well non-adherent plates in fresh expansion media for a further 2 days before being changed to osteoinductive media (Section 2.1.6).
Evaluating the effect of different BMP-2 plasmids on MSC osteogenesis in 3D collagen hydroxyapatite gene-activated scaffolds
Gene-activated scaffolds carrying either: CS-p CAG BMP-2, CSp CMV BMP-2/7, CS-p CMV BMP-2-Adv or CS-p EF1α BMP-2-Adv as well as untransfected, CS-empty and CS-CMV GFP controls, were fabricated as described in Section 2.2.2. After 28 days in culture, the scaffolds were removed from the wells and washed in PBS prior to further analysis. Alizarin red staining was used to investigate the level of mineralisation within the scaffolds. Samples were fixed with 10% formalin for 30 min and processed overnight using an automatic tissue processor (ASP300, Leica, Germany). The constructs were embedded in paraffin wax before sectioning. Sections of 5 μm thickness were cut using a rotary microtome (Microsystems GmbH, Germany) and sections were mounted on poly-L-lysine coated glass slides (Thermo Scientific, Ireland). Samples were deparaffinised with xylene and rehydrated before being stained in 2% alizarin red for 2-3 min. Sections were then dehydrated and DPX mountant was used to attach cover slips to the slides. Digital images of all stained sections were obtained using an imaging system (AnalySIS, Nikon, Japan) in conjunction with a microscope (Olympus IX51, Olympus, Japan). Calcium content per scaffold was quantified using a Stanbio calcium assay (Calcium CPC Liquicolour, Stanbio Inc., USA) 14 and 28 days post cell seeding. Briefly, media was removed and the scaffolds were placed in 1 mL of 0.5 M HCl and left shaking overnight at 4°C. Calcium levels were then quantified according to the manufacturer's instructions. The number of animals used per group to ensure a statistically powerful study was calculated using G*Power software based on previous studies using the calvarial defect model [12] . Anaesthesia was induced with intraperitoneal medetomidine hydrochloride (0.3 mg/kg) and ketamine hydrochloride (70 mg/kg) and maintained with inhalational isoflurane (0.5-2%) and oxygen. The skin of the head was shaved and cleaned using 70% ethanol and chlorhexidine before the animal was placed in the prone position on a heated aseptic operating platform prior to draping. A 3 mm sagittal skin incision over the calvarium was made and the soft tissues dissected using a blunt technique to expose the periosteum. A 7 mm trephine drill was used to create a 7 mm circular transosseous defect under constant irrigation with 0.9% NaCl. Scaffolds with a diameter of 8 mm and a height of 1.5 mm were press-fit into the defect and the periosteum and superficial connective tissue were closed in layers with 3-0 absorbable monofilament sutures (Monocryl™) and the skin was closed using a topical skin adhesive (n-butyl cyanoacrylate). Post-operatively, the animals were given a subcutaneous injection of the reversal agent atipamezole hydrochloride (0.05 mg/kg body weight) to reverse sedation. Animals were placed in an incubator at 35°C until fully recovered. Animals were housed (4 per cage) with ad libitum access to water, food and environmental enrichment. Antibiotics (enrofloxacin 2.5% − 10 mg/kg) were provided in the drinking water for 3 days post-surgery. At 4 weeks post-surgery, the animals were euthanised by CO 2 asphyxiation and cervical dislocation. A 20 mm × 20 mm section of the calvarium containing the defect was resected using a dental saw and the tissue was fixed for 72 h in 10% formalin before being transferred to Dulbecco's PBS.
Micro-computed tomography
The 20 mm × 20 mm sections of bone were analysed using micro computed tomography (μCT). Scans were performed on a Scanco Medical 40 MicroCT system (Scanco Medical, Bassersdorf, Switzerland) with a voxel resolution of 12 μm, a voltage of 70 kVP and a current of 112 μA. 3D reconstruction was performed using the standard Scanco software package with a threshold of 140 in a scale from 0 to 1000, corresponding to a density of 257.99 mg HA/ccm. These settings have been optimised for the rat calvarial model previously and are routinely used within our group [12, 17, [33] [34] [35] [36] . Volume of interest (VOI) was defined to analyse a 6 mm defect region to assess healing in the centre of the defect and to exclude any old bone at the defect edges. Repair was expressed as percentage of bone volume fraction within the defect area.
Histology and histomorphometry
To confirm the μCT results, both qualitative and quantitative histology was performed on explants. The explants were first decalcified using Decalcifying Solution-Lite (Sigma-Aldrich, Ireland) for a total of 13 h before specimens were dehydrated in a graded series of ethanol solutions using an automated tissue processor, bisected and embedded in single paraffin wax blocks. Sections (7 μm thick) were cut from the mid-portion of each sample using a rotary microtome and mounted on poly-L-lysine coated glass slides. Each section was stained with Haematoxylin and Eosin (H&E). Haematoxylin stains cell nuclei purple, eosin stains extracellular matrix pink and bone appears dark pink/red. Images of each specimen were acquired and digitised using transmitted light microscopic visualization (Nikon Microscope Eclipse 90i with NIS Elements software v3.06, Nikon Instruments Europe, The Netherlands). Quantitative analysis was performed on n = 6 sections from each specimen (n = 8 per group). Single blinded histomorphometric analysis was carried out in order to quantify the healing response from the H&E-stained samples. The defect margin was identified and any new bone was delineated using colour thresholding which allowed the quantification of the area of bone nucleation sites (BNS) in each section and calculation of the mean total area of these sites per group. This was performed using an automated Image J script [37] .
Immunohistochemistry analysis to determine osteoinductive effect of scaffolds
Immunohistochemical staining of paraffin embedded sections was carried out to assess the osteoinductive effect of the scaffolds on infiltrating endogenous cells by staining for key checkpoint markers of osteoblast differentiation from progenitor cells. Col1a1 (osteoprogenitor cells undergoing differentiation), and osteocalcin (mature osteoblasts) were used to identify cells at both stages of differentiation using rabbit IgG polyclonal antibodies (Santa Cruz Biotech., Germany). Two samples per animal were analysed (n = 8). Samples were prepared for staining by deparaffinisation and rehydration, followed by heatactivated citrate-based antigen retrieval. Samples were then incubated with a 1% H 2 O 2 peroxidase inhibitor (ThermoScientific, Ireland), before blocking in 5% horse serum (ThermoScientific, Ireland). Samples were then incubated at 4°C overnight with a 1:100 dilution of each corresponding primary antibody. To complete staining, a goat IgG Vectastain Elite ABC Kit was used in combination with a DAB Substrate kit (all from Vector labs, UK) according to manufacturer's instructions. Finally, the sections were counterstained using Mayer's haematoxylin counterstaining and mounted with DPX (ThermoScientific). Digital imaging was performed using the Nikon Eclipse 90i digital microscope system and five random sections were acquired for each specimen. Image J software was utilised to quantify % area of positive DAB staining using the automated pixel saturation method as in Section 2.3.3.
Statistical analysis
Results are expressed as mean ± standard deviation. Statistics were carried out using Graphpad Prism software using a general linear model ANOVA with post-hoc analysis performed for multiple comparisons. p < 0.05 values were considered statistically significant where * p < 0.05, ** p < 0.01 and *** p < 0.001.
Results
Comparison of BMP-2 protein production and functionality following transfection with modified BMP-2 plasmids
To confirm the optimal pDNA dose required to elicit the highest level of protein production while simultaneously avoiding cellular toxicity, a pDNA dose response study was carried out. pDNA doses of 0.5, 1, 2, 5 and 10 μg were delivered to cells at a constant N/P ratio of 20. In Fig. 2A -E the nanoparticles (red) at each pDNA dose can be seen surrounding the cells (green) 5 h post-transfection and evidence of nanoparticle aggregation can be seen at the higher pDNA doses of 5 and 10 μg. A pDNA dose of 2 μg/well induced the highest level of BMP-2 protein production, significantly higher than all other doses, at 3 days post-transfection (Fig. 2F) . Furthermore, at doses of 5 and 10 μg/well, significant cytotoxicity was observed and, likely due to the sheer number of nanoparticles binding to the cell membrane. Therefore, the optimal pDNA dose was found to be 2 μg/well at an N/P ratio of 20, confirming previously published data [16] .
The transient expression of BMP-2 protein by cells over time was also monitored using ELISA (Fig. 3) using the optimal nanoparticle formulation of N/P 20 carrying 2 μg of pDNA. As expected, there was no increase in BMP-2 protein production by cells that were either untransfected, transfected with CS-empty or CS-p CMV GFP thus confirming that the CS nanoparticles are not affecting BMP-2 production. All cells treated with a BMP-2 plasmid responded by significantly increasing BMP-2 protein production over controls at day 3 and 7 (p < 0.05), indicating positive transfection. The CS-p CMV BMP-2/7 treated cells produced significantly more BMP-2 compared to cells treated with p CAG BMP-2. Encouragingly, both BMP-2-Adv plasmids significantly enhanced BMP-2 protein production by tranfected cells when compared to all other groups (p < 0.001), and at the earlier time-point of day 3. In particular, the p CMV BMP-2-Adv proved to be the most efficient plasmid for inducing BMP-2 protein production by MSCs even when compared to p EF1α BMP-2-Adv.
To assess if the BMP-2 protein produced by transfected cells retained its osteoinductive properties, alkaline phosphatase activity was monitored at days 1, 3, 7 and 14 post-transfection. There was no increase in ALP activity in untransfected cells cultured in growth media (GM) for 14 days (Fig. 4A) . When untransfected cells were cultured in osteogenic media (Fig. 4B) , there was a significant increase in ALP activity at days 3 and 7 (p < 0.05) and similar levels of ALP activity were seen in cells treated with CS-empty (Fig. 4C) and CS-p CMV GFP (Fig. 4D) . ALP activity was significantly increased following treatment with each BMP-2 plasmid however p CMV BMP-2-Adv induced the highest level of ALP activity (Fig. 4G) . Interestingly, ALP activity peaked at day 7 in cells transfected with CS-p CAG BMP-2 ( Fig. 4E) and CS-p CMV BMP-2/ 7 ( Fig. 3F) while an earlier peak in ALP activity at day 3 was evident in the cells transfected with CS-p CMV BMP-2-Adv and CS-p EF1α BMP-2-Adv ( Fig. 4G and H) .
To confirm the osteoinductive effect of the BMP-2 protein produced by cells post-transfection on MSC osteogenesis, calcium deposition by transfected cells was quantified 14 days after transfection (Fig. 5) . As with the ALP activity experiments (Fig. 4) , all cells were cultured in osteoinductive media (Section 2.1.6) from day 3 post-transfection with the exception of the untransfected GM control with GM denoting growth media. As expected, the cells in osteoinductive media (OM) deposited more calcium than the untransfected cells in GM (p < 0.01). Calcium deposition by the control cells -untransfected in OM, CSEmpty and CS-p CMV GFP, was similar while all cells transfected with a pBMP-2 plasmid induced significantly more calcium deposition. Comparing CS-pBMP-2 transfected groups, it was evident that the CSp CMV BMP-2-Adv treated cells deposited significantly more calcium than other groups (p < 0.001) including the CS-p EF1α BMP-2-Adv group (p < 0.05).
Comparison of BMP-2 protein functionality following transfection with modified BMP-2 plasmids on a 3D collagen hydroxyapatite scaffold
Having confirmed the osteoinductive effects of the BMP-2 plasmids in 2D monolayer, and therefore the ability of the CS nanoparticles to effectively deliver the plasmids to MSCs, we then tested the efficacy of the modified plasmids when incorporated into a gene-activated collagen hydroxyapatite (CHA) scaffold. Calcium deposition by cells was used as an indicator of MSC osteogenesis and was assessed using alizarin red staining at 28 days post-transfection while calcium content within the scaffolds was quantified at days 14 and 28. As with the 2D experiments, all cells were cultured in osteoinductive media with the exception of the untransfected GM group. The images shown in Fig. 6 represent full scans of the scaffolds stained with alizarin red 28 days post-transfection. It is evident that there was more positive staining in the scaffolds containing BMP-2 plasmids but the CS-p CMV BMP-2-Adv Fig. 3 . Assessment of BMP-2 protein production by transfected cells. Untransfected cells were compared to cells treated with CS-empty, CS-p CMV GFP, CSp CAG BMP-2, CS-p CMV BMP-2/7, CS-p CMV BMP-2-Adv and CS-p EF1α BMP-2-Adv. BMP-2 protein production as monitored by ELISA at day 1, 3, 7 and 14 posttransfection. Each of the four BMP-2 plasmids induced cells to produce more BMP-2 protein than controls. The p CMV BMP-2-Adv induced cells to produce significantly more BMP-2 protein than all other groups at days 3, 7 and 14. Data plotted represents mean ± SD where n = 3. Two-way ANOVA followed by Bonferroni post hoc analysis was performed and * represents p < 0.05 and *** represents p < 0.001. treated group appears to have stained more intensely for mineral. When calcium deposition was quantified (Fig. 6) , there was no significant difference in calcium content between untransfected cells in growth versus osteoinductive media at each time point, reflecting the inherent osteoinductive nature of the collagen hydroxyapatite scaffold. However, the pBMP-2 treated groups deposited significantly more calcium than the control groups as is particularly evident at day 28 and again, CS-p CMV BMP-2-Adv induced significantly more calcium deposition than all other groups.
Efficacy of gene-activated scaffold in accelerated repair of critical sized bone defects in vivo
From the in vitro testing in both 2D monolayer and in 3D gene-activated scaffolds, it was established that CS-p CMV BMP-2-Adv was the most efficient at inducing MSC osteogenesis. We then sought to investigate the efficacy of the gene-activated scaffold loaded with CSp CMV BMP-2-Adv in vivo in a critical sized calvarial defect (n = 8) using an established rat model. To confirm that this plasmid is more efficient than p CAG BMP-2, we also included CS-p CAG BMP-2 activated scaffolds as a control (n = 8) as well as a gene-free scaffold (n = 8) and an untreated control (n = 8). Recently published work has shown that geneactivated scaffolds are capable of accelerating bone formation [12, 17] , thus an early time-point of 4 weeks was chosen for assessment. As 7 mm represents a critical-sized defect, the lack of repair in the untreated group was expected (Fig. 7A) . The gene-free collagen hydroxyapatite scaffold has previously been shown to heal defects by 8-12 weeks [35, 38] so the low level of bone formation visible in Fig. 7B at this early time-point was expected. The CS-p CAG BMP-2 activated scaffold induced some de novo bone formation (Fig. 7C) ; however, the CS-p CMV BMP-2-Adv activated scaffold induced significantly more bone formation compared to all other groups (Fig. 7D) . When the new bone volume fraction was calculated, the CS-p CMV BMP-2-Adv activated scaffold significantly enhanced bone formation (Fig. 7E) . Analysis of trabecular number (Fig. 7F), trabecular thickness (Fig. 7G ) and trabecular spacing (Fig. 7H ) confirmed this result with a significantly higher number of trabeculae and thus less space between trabeculae in the animals treated with CS-p CMV BMP-2-Adv activated scaffold compared to other groups. Trabecular thickness did not vary between groups.
Histological analysis of the calvarial tissue explants was consistent with the microCT results. When stained using H&E, the untreated defect explants had minimal new bone within the defect (pink) and consisted mainly of fibrous tissue (Fig. 8A) . More bone nucleation sites were 5 . Effect of osteoinductive genes on MSC osteogenesis in 2D monolayer as measured by calcium deposition quantification. Untransfected cells in growth media (GM) and osteoinductive media (OM) were compared to cells treated with CS-empty, CS-p CMV GFP, CS-p CAG BMP-2, CS-p CMV BMP-2/7, CS-p CMV BMP-2-Adv and CS-p EF1α BMP-2-Adv. Calcium deposition was quantified 14 days post-transfection. Each condition induced cells to produce significantly more calcium than untransfected cells in growth media. Each variant of BMP-2 plasmid induced significantly more calcium deposition than controls without a BMP-2 plasmid. The CS-p CMV BMP-2-Adv transfected group induced significantly higher levels of calcium deposition compared to all other groups. Data plotted shows mean ± standard deviation (n = 3). One-way ANOVA followed by Tukey post hoc analysis was performed and * indicates p < 0.05, **p < 0.01 and ***p < 0.001. evident in the gene-free and CS-p CAG BMP-2 activated scaffolds but the majority of the tissue was fibrous in nature and the scaffold was visible ( Fig. 8B and C) . In contrast, animals treated with the CS-p CMV BMP-2-Adv activated scaffolds have large areas filled with new bone (Fig. 8D) . The area of new bone was quantified using an automated Image J programme based on pixel intensity (Fig. 8E) and confirmed that the CS-p CMV BMP-2-Adv activated scaffold induced significantly more bone formation compared to the other groups (p < 0.05 to p < 0.001). While there was no significant difference between the untreated, gene free scaffold and CS-p CAG BMP-2 activated scaffold groups, the results show a trend towards greater healing in treated versus untreated groups with untreated < gene-free scaffold < CS-p CAG BMP-2 activated scaffold < CS-p CMV BMP-2-Adv activated scaffold.
Immunohistochemistry was then performed to further analyse the process of bone formation of each of the groups. Col1a1 is a marker of early stage bone formation, being expressed by differentiating osteoprogenitor cells, while osteocalcin is a marker of late stage bone formation, being expressed by mature osteoblasts. Samples were stained Fig. 6 . Effect of osteoinductive genes on MSC osteogenesis in 3D collagen hydroxyapatite scaffolds as measured by calcium deposition quantification. Untransfected cells in growth media (GM) and osteoinductive media (OM) were compared to cells treated with CS-empty, CS-p CMV GFP, CS-p CAG BMP-2, CS-p CMV BMP-2/7, CS-p CMV BMP-2-Adv and CSp EF1α BMP-2-Adv. Calcium deposition was quantified 14 and 28 days post-transfection. Mineral deposition (red) is seen in the 4× scans of each scaffold with more mineral evident in the BMP-2 treated groups over the controls. When calcium content was quantified, each condition induced cells to produce significantly more calcium than untransfected cells in growth media. Each variant of BMP-2 plasmid induced significantly more calcium deposition than controls without a BMP-2 plasmid. The CS-p CMV BMP-2-Adv transfected group induced significantly higher levels of calcium deposition compared to all other groups. Data plotted shows mean ± standard deviation (n = 3). Two-way ANOVA followed by Bonferroni post hoc analysis was performed and and * indicates p < 0.05 and ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 7 . MicroCT analysis of bone repair in critical sized bone defects after 4 weeks. Critical size (7 mm) bone defects in the rat calvarium were A) untreated; or B) treated with a gene-free scaffold; C) a CS-p CAG BMP-2 activated scaffold; or D) a CS-p CMV BMP-2-Adv activated scaffold. Tissue was harvested 4 weeks post-implantation and new bone formation and quality was quantified using microCT. Representative reconstructed images show enhanced bone formation in the CSp CMV BMP-2-Adv scaffold group compared to control groups and when quantified, this was a significantly higher amount of new bone volume fraction (E). The quality of bone was also improved as indicated by trabecular number (F), trabecular thickness (G) and trabecular spacing (H). Data plotted shows mean ± standard deviation (n = 8). One-way ANOVA followed by Tukey post hoc analysis was performed and * indicates p < 0.05 and ***p < 0.001. using antibodies targeting Col1a1 (Fig. 9, top panel) and osteocalcin (Fig. 9 , bottom panel) and clear differences were evident between groups. The explants from untreated animals (Fig. 9A) did not stain positively for either Col1a1 or osteocalcin, indicating that healing has not begun to any notable level. As this is a critical sized defect and with the lack of bone formation evident from microCT and histological analysis (Figs. 7 and 8 ), this result is consistent with the rest of the study. There was positive staining for both markers in explants from animals treated with gene-free scaffolds (Fig. 9B) , CS-p CAG BMP-2 activated scaffolds (Fig. 9C) and CS-p CMV BMP-2-Adv activated scaffolds (Fig. 9D ) although more positive staining is clearly evident in the latter. Using a similar automated Image J programme based on pixel intensity as described in Fig. 8 , positive staining was quantified. Animals treated with the gene-free scaffolds and CS-p CAG BMP-2 activated scaffolds contained significantly more Col1a1 than untreated controls (p < 0.05 and p < 0.01 respectively) while in explants from animals treated with CS-p CMV BMP-2-Adv activated scaffolds, Col1a1 staining was significantly higher than all other groups (p < 0.001) (Fig. 9E) . The same trend was evident when positive staining for osteocalcin was quantified although no significant differences were found between untreated, gene-free scaffolds and CS-p CAG BMP-2 activated scaffolds. Explants from animals treated with CS-p CMV BMP-2-Adv activated scaffolds had significantly more osteocalcin present compared to all other groups (Fig. 9F) .
Interestingly, there was more positive staining for Col1a1 versus osteocalcin in the gene-free scaffolds which may indicate that the bone healing process was at an earlier stage (Fig. 9G) . This result is consistent with the hypothesis that gene-activated scaffolds can accelerate bone healing as well as previous work which showed healing of defects after 8-12 weeks using the gene-free scaffold [35, 38] . Conversely, there was more positive staining for osteocalcin versus Col1a1 in the CS-p CMV BMP-2-Adv activated scaffold which indicates that healing is at a later stage. Taken together, this study confirms that optimising the plasmid construct can translate to increased protein formation and confer enhanced therapeutic functionality to the gene-activated scaffold.
Discussion
BMP-2 delivery for bone repair has a gained a lot of bad press due to adverse side effects reported following uncontrolled release of supraphysiological doses of recombinant protein [39, 40] which are required due to the short half-life of proteins in physiological conditions. Delivering genes encoding for the BMP-2 protein to host cells, instead of high doses of protein, circumvents the requirement for high dosing regimes as the cells begin to produce the required protein themselves. "Gene delivery can be used to manipulate cells to produce therapeutic proteins themselves, thus controlling the release of physiological quantities of protein over time. The combination of gene delivery with tissue engineered biomaterial scaffolds allows for localised delivery of therapeutic to the defect site, thus limiting off-target side effects as well as providing a template for new tissue formation. The gene-activated scaffold system described in this paper is highly translatable as the base collagen hydroxyapatite scaffold has already undergone signficant preclinical testing and is currently being used to treat defects in human patients [35, 36, [41] [42] [43] [44] . The chitosan nanoparticles have been shown to be biocompatible and biodegradable unlike many polymer or lipidbased non-viral gene delivery vectors while maintaining a high transfection efficiency [45, 46] . Furthermore, previous work within our group has shown that the gene-activated scaffold has a good safety profile as the gene therapeutic was retained at the defect site, and was capable of accelerating bone repair in a rodent calvarial model of critical-sized bone defects when both p CAG BMP-2 and p CMV VEGF were Fig. 8 . Histological analysis of bone repair in critical sized bone defects after 4 weeks. Representative H&E images of explants from calvarial defects at 4× and 20× magnification. H&E staining indicates bone in dark pink. A) Untreated; B) Gene-free scaffold; C) CS-p CAG BMP-2 activated scaffold; D) CS-p CMV BMP-2-Adv activated scaffold. Histomorphological analysis using an automated pixel intensity method (E) confirmed that the CS-p CMV BMP-2-Adv activated scaffold significantly enhanced new bone formation compared to CS-p CAG BMP-2 activated scaffolds and controls after 4 weeks (F). Data plotted shows mean ± standard deviation (n = 8). One way ANOVA followed by Tukey post hoc analysis was performed and * indicates p < 0.05, ** p < 0.01 and *** p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) delivered. However, the efficacy of a p CAG BMP-2 gene-activated scaffold on its own was low in comparison [17] ." The aim of this study was to investigate if improved BMP-2 plasmids could increase the efficiency of the gene-activated scaffold system and enhance bone repair in critical-sized defects.
The first objective of this study was to compare BMP-2 protein expression and functionality following transfection of MSCs with each of the BMP-2 plasmids. The use of a multi-cistronic plasmid was assessed to determine if heterodimeric BMP-2/7 expression enhanced bone formation over homodimeric BMP-2 expression [20] . The results show that p CMV BMP-2/7 delivery did not enhance BMP-2 production over p CAG BMP-2, however, this may be due to heterodimer formation rather than low expression of BMP-2 protein. This result is in agreement with previous studies which showed low BMP-2 production following transfection with the same p CMV BMP-2/7 plasmid and may be due to an inability of the ELISA kit to detect the heterodimeric form of BMP-2/7 [20, 47] . Interestingly, the level of BMP-7 produced by pBMP-2/7 transfected cells was 5-fold higher than BMP-2 expression post-transfection with p CMV BMP-2/7 ( Supplementary Fig. 1 ), in line with previous studies [19, 20] indicating that perhaps during post-transcriptional modifications, the cells are producing more BMP-7 homodimers than BMP-2 homodimers or BMP-2/7 heterodimers. The p CMV BMP-2-Adv and p EF1α BMP-2-Adv plasmids both contained a highly truncated artifical intron sequence and codon optimisation was performed to enhance transcription rate and translation of BMP-2 protein.
Subsequently, the p CMV BMP-2-Adv plasmid in particular induced faster and higher BMP-2 production by cells compared to p CAG BMP-2, p CMV BMP-2/7 and even p EF1α BMP-2-Adv reaching a peak of approximately 30 ng/mL at days 3 and 7. In contrast, here and in previous studies, peak protein expression was observed at day 10 post-transfection when p CAG BMP-2 was used [17] . This indicates that the modifications to the BMP-2 gene carried out in the construction of the BMP-2-Advanced plasmids accelerated transcription and translation rates and the CMV promoter outperformed the EF1α promoter. Most encouragingly, the level of protein production by MSCs transfected with the non-viral CS-p CMV BMP-2-Adv was comparable to recently reported results delivering the BMP-2 gene using an adenoviral vector [48] .
The BMP-2 protein produced by transfected cells was functional, with increased ALP activity by MSCs transfected with each BMP-2 encoding plasmid. Interestingly, ALP activity in cells transfected with both BMP-2-Advanced plasmids peaked at the earlier time-point of day 3 compared to the later peak at day 7 in cells transfected with p CAG BMP-2 and p CMV BMP-2/7. Calcium deposition was also highest in cells treated with p CMV BMP-2-Adv. These results indicate that insertion of a highly truncated intron sequence into the BMP-2 gene, along with codon optimisation, resulted in more efficient transcription and translation of the BMP-2 gene leading to earlier and higher protein production and earlier osteogenic response by cells following transfection with p CMV BMP-2-Adv.
The results from experiments carried out in 2D remained consistent when the plasmids were incorporated into collagen hydroxyapatite (CHA) scaffolds. The CHA scaffold was already shown to be osteoinductive due to the presence of hydroxyapatite crystals [41] but by loading the scaffold with CS nanoparticles carrying each BMP-2 plasmid, the osteoinductive potential of the scaffold was significantly enhanced. Alizarin red staining and calcium quantification showed that the CS-p CMV BMP-2-Adv activated scaffold was the most osteoinductive with approximately 2500 μg of calcium deposited by MSCs after 28 days. This result surpasses recent reports using the scaffold to deliver pBMP-2 with pVEGF [12, 17] as well as previous papers delivering rhBMP-2 [35, 36] , highlighting the efficiency of the p CMV BMP-2-Adv plasmid.
Due to the efficiency of the CS-p CMV BMP-2-Adv activated scaffold in vitro, it was taken forward for implantation into a 7 mm calvarial defect in a rodent model and compared to CS-p CAG BMP-2 activated scaffolds, gene-free scaffolds, and untreated controls. This model was chosen as it is well established within our group and allows for direct comparison between different scaffolds with and without additional therapeutics. Furthermore, as the calvarium is not load-bearing, variability between animals can be reduced although testing in large load-bearing defects such as the femur remains a requirement towards translation of these products. In the calvarial model, the 7 mm defect is well established as being of a critical-size [49] and consistent with this, no healing was observed in the empty defect group. MicroCT and histomorphometry analysis at 4 weeks post-implantation showed that a significantly higher quantity of new bone was present within the defect in animals treated with the CS-p CMV BMP-2-Adv activated scaffold compared to the other groups. The bone was also of higher quality to that of control groups as indicated by trabecular number. The results at this early time-point are impressive as most previous studies do not show a similar level of healing until 6-8 weeks post-implantation [50, 51] . Furthermore, the results are comparable to a recent study using chitosan films loaded with five times the dose of pBMP-2 (10 μg versus 2 μg used in this study) [52] . Another study using chitosan nanoparticles to deliver pBMP-2 within a chitosan hydrogel showed promising results although the defect was smaller (5 mm versus 7 mm in this study) and the methods used to determine new bone formation were qualitative rather than quantitative, making it difficult to draw comparisons [53] .
Of most interest in this study was the difference in bone formation observed between the gene-activated scaffolds loaded with a BMP-2 plasmid versus the BMP-2-Advanced plasmid. The CS-p CAG BMP-2 activated scaffold induced low levels of bone formation, no different to the gene-free scaffolds or indeed the untreated controls. While somewhat surprising, it may be that these treatments require more time to exert an osteoinductive effect. From previous work within our group, it was shown that the CHA scaffold can induce bridging of critical sized defects at 8 weeks post-implantation [38] . As was shown by the in vitro data, cells transfected with CS-p CAG BMP-2 took longer to express BMP-2 protein, increase ALP activity, or deposit calcium compared to CSp CMV BMP-2-Adv transfected cells, therefore it is a reasonable assumption that the osteoinductive response of host cells to the CS-p CAG BMP-2 activated scaffold might be delayed. To investigate further, immunohistochemistry was carried out looking at early (Col1a1) and late (osteocalcin) stage markers of bone formation [54] . As hypothesised, more active bone formation was promoted by the CS-p CMV BMP-2-Adv scaffold compared to the other groups. However, there was more Col1a1 positive staining in the CS-p CAG BMP-2 activated scaffold compared to the untreated control, indicating that there was some bone formation taking place. Interestingly, in the CS-p CMV BMP-2-Adv activated scaffold group, there was more osteocalcin present than Col1a1 which may indicate that the induced bone is at a more mature stage. Conversely, in the CS-p CAG BMP-2 activated scaffold and gene-free scaffold treated animals, there was more Col1a1 than osteocalcin present indicating that bone formation was at an earlier stage. These results support the hypothesis that the BMP-2-Advanced plasmid can accelerate bone formation.
Conclusions
This study revealed that by using a modified BMP-2 plasmid, transcription and translation of the BMP-2 protein can be enhanced leading to earlier and higher levels of BMP-2 protein expression, increased ALP activity at an earlier time-point and enhanced calcium deposition. In vitro results were translated in vivo with significantly more bone formation observed at the early time-point of 4 weeks in defects treated with p CMV BMP-2-Adv compared to the p CAG BMP-2, and demonstrated that this result was due to delayed expression of lower levels of the bone markers Col1a1 and osteocalcin. Taken together, this study confirms that by optimising the plasmid construct, it is possible to accelerate and increase protein production and confer enhanced functionality to the gene-activated scaffold. This system essentially acts as a single-treatment therapeutic factory, inducing host cells which readily infiltrate the scaffold to produce BMP-2 at physiological levels, resulting in enhanced bone repair. Furthermore, the transient protein expression induced by the non-viral vector overcomes concerns associated with gene therapy and reduces the risk of off-target side effects. The gene-free collagen hydroxyapatite scaffold used in this study has already undergone rigorous in vitro and in vivo [31, 42, 55] testing and is now in human clinical use (marketed as HydroxyColl™ by SurgaColl Technologies) making this next generation gene-activated scaffold a highly translatable therapy for critical sized or non-union bone defects.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jconrel.2018.05.022.
